๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
NCT05940961ALL, MRD-positive, Hematopoietic Stem Cell Transplantation
Sheng-Li Xue, MD
Phase 2
42
Suzhou
2022-08-01
Recruiting
Establishment of the Chinese Preclinical Alzheimer's Disease Study With Multiple Neuroimaging
NCT06827678Alzheimer Disease, Positron Emission Tomography
Huashan Hospital
Observational
3,000
Shanghai
2022-08-01
Recruiting
ZR2 Sequential Immunochemotherapy for Newly Treated MCL
NCT05992597Rituximab, Lenalidomide, Zebutinib ๏ผŒMantle Cell Lymphoma
Zhejiang Cancer Hospital
Phase 2
48
Hangzhou
2022-08-01
Recruiting
An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment
NCT05486650Non Small Cell Lung Cancer
Xinqiao Hospital of Chongqing
Observational
20
Chongqing
2022-08-01
Recruiting
Eluvia DES for the Patients with Femoropopliteal Artery Lesions.
NCT05522218Vascular Diseases, Stent Complication
First Affiliated Hospital of Zhejiang University
Observational
400
Hangzhou
2022-08-01
Active, closed
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
NCT05133531Paroxysmal Nocturnal Hemoglobinuria
Regeneron Pharmaceuticals
Phase 3
202
Beijing
2022-08-01
Recruiting
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
NCT06006650Neoadjuvent, PD-1 Inhibitor, Chemotherapy, Esophageal Squamous Cell Carcinoma
Tang-Du Hospital
Phase 2
114
Xi'an, Xiโ€™an
2022-08-01
Not yet open
Intervention of Suxiao Jiuxin Pill on Instability of Vulnerable Plaque in Acute Myocardial Infarction
NCT05466968Acute Myocardial Infarction
Xiaolu Li
Phase 4
116
Jinan
2022-08-01
Recruiting
The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
NCT05263570Breast Cancer
Shengjing Hospital
Observational
200
Shenyang
2022-08-01
Not yet open
Effects of Non-surgical Periodontal Therapy on Cardiovascular Risk
NCT05459727Cardiovascular Diseases, Periodontitis
Nanfang Hospital, Southern Medical University
Not applicable
376
Guangzhou
2022-08-01
Recruiting
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
NCT05660473Precursor Cell Lymphoblastic Leukemia-Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
100
Tianjin
2022-08-01
Active, closed
Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation
NCT05491811Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 2
47
Guangzhou
2022-08-01
Active, closed
Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)
NCT05306028Pancretic Cancer, Diabete Mellitus
Fudan University
Phase 2
20
Shanghai
2022-08-01
By invitation
Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA
NCT07299123Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Refractory, Severe Aplastic Anemia
Chinese PLA General Hospital
Phase 1/2
40
Beijing
2022-08-01
Recruiting
Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
NCT05392413Esophageal Squamous Cell Carcinoma, PD-1 Inhibitor
Nanfang Hospital, Southern Medical University
Observational
200
Guangzhou
2022-08-01
Not yet open
Acupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
NCT05460819Hot Flashes, Breast Cancer, Acupuncture
Nanjing University of Traditional Chinese Medicine
Not applicable
90
Nanjing
2022-08-01
Active, closed
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
NCT05463601Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
132
Guangzhou
2022-08-01
Recruiting
Clinical Indicators and Brain Image Data: a Study Based on Kailuan Cohort
NCT05453877Brain Diseases, Hypertension
Beijing Friendship Hospital
Observational
1,000
Beijing, Tangshan
2022-08-01
Recruiting
Lateral Pelvic Lymph Node Dissection for Rectal Neuroendocrine Neoplasms Undergoing Laparoscopic Total Mesenteric Excision
NCT06279299Rectal Neuroendocrine Neoplasm
National Cancer Center, China
Not applicable
30
Beijing
2022-08-01
Recruiting
Dual-Port Laparoscopic Distal Gastrectomy for Gastric Cancer
NCT05494086Gastric Cancer
Nanfang Hospital, Southern Medical University
Not applicable
300
Guangzhou
2022-08-01
Recruiting
Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology
NCT05306509Solid Tumor, Hematological Malignancies
Children's Hospital of Fudan University
Not applicable
120
Shanghai
2022-08-01
Not yet open
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
NCT05303727Neuroblastoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
64
Guangzhou
2022-08
Recruiting
To Assess the Safety and Efficacy of the Atrial Shunt Implant System in the Treatment of Patients With Chronic Left Heart Failure
NCT05486000Left Heart Failure
Morningside (Nantong) Medical Co.,Ltd
Not applicable
120
Nantong
2022-08
Recruiting
Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration
NCT05445063Macular Degeneration
Beijing Tongren Hospital
Phase 1
10
Beijing
2022-08
Recruiting
Efficacy of Probiotics in Patients With IBD
NCT05652621Ulcerative Colitis, Irritable Bowel Syndrome
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
200
Xinxiang
2022-07-31
Recruiting
Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
NCT05707819Nasopharyngeal Carcinoma, Sintilimab
Cancer Hospital of Guangxi Medical University
Observational
43
Nanning
2022-07-30
By invitation
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
NCT06048926Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Not applicable
30
Nanjing
2022-07-30
Active, closed
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
NCT05457257Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 4
43
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2022-07-29
Recruiting
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
NCT05727163Colorectal Cancer Metastatic
Sun Yat-sen University
Phase 2
194
Guangzhou
2022-07-29
Recruiting
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT05379595Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC
Phase 1/2
225
Dalian, Guangzhou, Hangzhou, Wuhan
2022-07-29
Recruiting
Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
NCT06870942HCC - Hepatocellular Carcinoma, Radiotherapy
Shanghai Zhongshan Hospital
Phase 2
35
Shanghai
2022-07-28
Recruiting
Correlation Between Postoperative Cognitive-related Adverse Reactions and Brain Metabolomic Characteristics in Elderly Patients
NCT05555693POCD - Postoperative Cognitive Dysfunction
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Observational
200
Shanghai
2022-07-27
Recruiting
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT06909877Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Haihe Biopharma Co., Ltd.
Phase 1/2
100
Chengdu
2022-07-27
Active, closed
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
NCT05899049Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
251
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2022-07-27
Recruiting
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
NCT05476432Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3
300
Foshan, Guangzhou
2022-07-26
Recruiting
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
NCT05377658Non-small Cell Lung Cancer
Henan Cancer Hospital
Phase 2
43
Zhengzhou
2022-07-26
Active, closed
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
NCT05502393Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
133
Chizhou, Fuzhou, Wuwei, Guangzhou, Meizhou, Shijiazhuang, Wuhan, Harbin
2022-07-26
Recruiting
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
NCT05472558B-cell Non Hodgkin Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
48
Hanzhou
2022-07-26
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
737
Changsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai
2022-07-22
Recruiting
Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods
NCT05501353Colorectal Cancer Metastatic
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
125
Hangzhou
2022-07-22
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
Janssen Research & Development, LLC
Phase 2
703
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Haikou
2022-07-22
Active, closed
V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)
NCT05450705Papillomavirus Infections
Merck Sharp & Dohme LLC
Phase 3
1,500
Quzhou, Taizhou
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC
Phase 2
189
Beijing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Xuzhou, Nanchang, Chuangchun
2022-07-21
Recruiting
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
NCT05067348Myasthenia Gravis, Generalized
Tang-Du Hospital
Phase 2
64
Beijing, Changsha, Xi'an, Shanghai, Chengdu, Tianjin
2022-07-21
Active, closed
Timing of Damage Control Orthopedic Surgery
NCT05785143The Precision Personal Timeline in Definitive Surgery Associated With Outcome
China Medical University Hospital
Observational
100
2022-07-20
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
Gilead Sciences
Phase 3
623
Beijing, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou, Harbin
2022-07-20
Active, closed
Hereditary Cerebral Small Vessel Diseases Registry-Trial Ready Cohort
NCT06512376Cerebral Small Vessel Diseases, Hereditary
Beijing Tiantan Hospital
Observational
100
Beijing
2022-07-19
Recruiting
A Study of FVIII Gene Therapy for Hemophilia A
NCT05454774Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
8
Tianjin
2022-07-19
Active, closed
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NCT05438329Advanced Solid Tumor
DualityBio Inc.
Phase 1/2
1,123
Bengbu, Hefei, Fuzhou, Lanzhou, Dongguan, Guangzhou, Guigang, Nanning
2022-07-19
Not yet open
Intraperitoneal Lidocaine in Ovarian Cancer Surgery
NCT05450055Ovarian Cancer, Post Operative Pain
Peking University Third Hospital
Not applicable
60
Beijing
2022-07-18
Active, closed
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
922
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou
2022-07-18
Recruiting
Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
NCT05443841Esophageal Cancer
Fudan University
Observational
385
Hefei, Shijiazhuang, Zhengzhou, Nantong, Taishing, Taizhou, Xi'an, Tianjin
2022-07-18
Recruiting
Long-Term Survival After LVAD Implantation in End-Stage Heart Failure
NCT07382284End-stage Heart Failure
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
300
Nanjing
2022-07-17
Recruiting
Omega-3, Autism Spectrum Disorder (ASD)
NCT07365553ASD
China Medical University Hospital
Not applicable
50
2022-07-15
Active, closed
Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)
NCT05453435Resolved Hepatitis B, CD20 Positive B-cell Lymphoma
Sun Yat-sen University
Phase 2
84
Guangzhou
2022-07-15
Active, closed
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05340270Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor
Guangxi Medical University
Phase 2
150
Nanning
2022-07-15
Active, closed
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934Eosinophilic Granulomatosis With Polyangiitis
GlaxoSmithKline
Phase 3
163
Beijing, Guangzhou, Hefei, Nanjing, Qingdao, Shanghai, Shenzhen, Wenzhou
2022-07-14
Active, closed
A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis
NCT05526222Atopic Dermatitis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
443
Changsha
2022-07-14
Recruiting
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
NCT05632380Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
20
Tianjin
2022-07-14
Active, closed
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277Lupus Nephritis
Novartis Pharmaceuticals
Phase 3
452
Guangzhou, Shantou, Shenzhen, Liuzhou, Haikou, Wuhan, Changsha, Nanjing
2022-07-14
Active, closed
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696Extensive Stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
55
Beijing, Shanghai
2022-07-13
Active, closed
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
NCT05246514HER2-mutant Non-Small Cell Lung Cancer
AstraZeneca
Phase 2
72
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-07-13
Recruiting
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
NCT06379113Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
Xiaojun Chen
Phase 2/3
29
Shanghai
2022-07-13
Active, closed
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
NCT06390904Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
Xiaojun Chen
Phase 2/3
29
Shanghai
2022-07-13
Recruiting
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
NCT05200260Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Phase 2
220
Foshan, Guangzhou, Hangzhou, Hefei, Shanghai
2022-07-13
Recruiting
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
NCT05316935Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance
Xiaojun Chen
Phase 2/3
80
Shanghai
2022-07-13
Active, closed
INSPIRIS China PMCF Study
NCT05404880Aortic Valve Replacement
Edwards Lifesciences
Observational
255
Hefei, Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Xiโ€™an
2022-07-13
Recruiting
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
NCT05487170Advanced Solid Tumor, DLBCL
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
32
Beijing
2022-07-12
Recruiting
Human BCMA Targeted T Cells Injection๏ผˆBCMA CAR-T๏ผ‰for Subjects With R/R MM
NCT05594797Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Phase 2
100
Shanghai, Wenzhou
2022-07-12
Recruiting
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)
NCT05165407Neuroendocrine Neoplasm
Peking University
Phase 2
30
Beijing
2022-07-12
Active, closed
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
NCT05460273Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer
AstraZeneca
Phase 1/2
119
Beijing, Bengbu, Changchun, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-07-11
Recruiting
Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
NCT05447169Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
11,625
Guangzhou
2022-07-10
Recruiting
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
NCT05461664Gastrointestinal Stromal Tumors, Unresectable Solid Tumor, Recurrent Metastatic Malignant Neoplasm
Xinhua Zhang, MD
Observational
74
Guangzhou
2022-07-10
Recruiting
A Study for the Adjuvant Treatment of Breast Cancer
NCT05420467Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
2,413
Hangzhou
2022-07-10
Recruiting
A Study for the Neoadjuvant Treatment of Breast Cancer
NCT05420454Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
1,576
Hangzhou
2022-07-10
Recruiting
Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
NCT07064746Neuroblastoma (NB)
Nanjing First Hospital, Nanjing Medical University
Observational
150
Nanjing
2022-07-10
Recruiting
A Prospective Cohort Study on Colorectal Cancer Screening in Community Population
NCT05485077Colorectal Cancer
Singlera Genomics Inc.
Observational
18,000
Beijing
2022-07-09
Recruiting
A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
NCT05464875Gastrointestinal Stromal Tumors, Unresectable Solid Tumor, Recurrent Metastatic Malignant Neoplasm
Xinhua Zhang, MD
Observational
74
Guangzhou
2022-07-09
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Daiichi Sankyo
Phase 3
586
Beijing, Changchun, Changsha, Chengdu, Chibi, Fuzhou, Guangzhou, Haidian
2022-07-08
Active, closed
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
NCT05360446Coronary Artery Disease
Novartis Pharmaceuticals
Phase 3
609
Beijing, Nanjing, Shanghai
2022-07-08
Active, closed
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
NCT05226871Breast Cancer, Head and Neck Cancer
Pfizer
Phase 2
35
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun, Shenyang
2022-07-07
Recruiting
A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
NCT06245330Solid Tumor, Pancreatic Cancer
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
180
Changchun
2022-07-07
Active, closed
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195Metastatic Breast Cancer
Novartis Pharmaceuticals
Phase 4
134
Chongqing, Shijiazhuang, Harbin, Changsha, Nanjing, Suzhou, Changchun, Kunming
2022-07-07
Recruiting
Regional Radiotherapy Omission in Low-Risk Node Positive Breast Cancer
NCT07179744Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
635
Guangzhou
2022-07-06
Recruiting
Safety and Efficacy of the HighLife Transcatherter Mitral Valve Replacement System in Patients With Moderate-severe or Severe Mitral Regurgitation in China
NCT05610566Mitral Regurgitation
Peijia Medical Technology (Suzhou) Co., Ltd.
Not applicable
110
Suzhou
2022-07-06
Recruiting
The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer
NCT05984485Rectal Cancer
Sun Yat-sen University
Phase 3
766
Chongqing, Guangzhou, Hengyang, Shenyang, Xi'an, Nanchong
2022-07-05
Active, closed
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
NCT05426733Biliary Atresia
Albireo, an Ipsen Company
Phase 3
180
Guangdong, Shanghai
2022-07-05
Recruiting
SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
NCT05300269Locally Advanced Rectal Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
73
Shanghai
2022-07-05
Recruiting
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease
NCT05439226Type 2 Diabetes
State Key Laboratory of Subhealth Intervention Technology
Not applicable
120
Yichang, Changsha
2022-07-05
Recruiting
Effects of CI on Tinnitus and Its Symptoms
NCT05453019Tinnitus
Chinese PLA General Hospital
Not applicable
200
Beijing
2022-07-04
Recruiting
Efficacy on Walking Ability of Electroacupuncture Therapy in Elderly Patients With Sarcopenia
NCT05431010Sarcopenia
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
120
Hangzhou
2022-07-02
Active, closed
Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT06196827Inherited Retinal Dystrophy Associated With RPE65 Mutations
Innostellar Biotherapeutics Co.,Ltd
Phase 1
9
Beijing, Shanghai
2022-07-02
Recruiting
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
NCT05628922Nasopharyngeal Cancer
Fudan University
Phase 2
198
Shanghai
2022-07-02
Recruiting
Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma
NCT06644352Siewert Type II Adenocarcinoma of Esophagogastric Junction
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
236
Beijing
2022-07-01
Recruiting
Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
NCT05433935Intraductal Papillary Mucinous Neoplasm
Zhejiang University
Observational
5,000
Hangzhou
2022-07-01
Active, closed
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
NCT05383716Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor
Peking Union Medical College Hospital
Phase 2
80
Beijing
2022-07-01
Recruiting
Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer
NCT05424159Pancreatic Cancer Non-resectable
Shanghai Proton and Heavy Ion Center
Not applicable
48
Shanghai
2022-07-01
Recruiting
A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer
NCT06082180Thyroid Cancer, Recurrence
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
1,199
Beijing
2022-07-01
Recruiting
Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases
NCT05476627Chronic Kidney Diseases, Hypertension, Diabetes Mellitus, Hyperuricemia
Peking Union Medical College Hospital
Observational
200
Beijing
2022-07-01
Recruiting
TAVR for Aortic Valve Disease
NCT05439863Aortic Valve Disease
Nanjing First Hospital, Nanjing Medical University
Observational
5,000
Nanjing
2022-07-01
Rows per page Showing 16401–16500 of 19052
Previous 163 164 165 166 167 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=165

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.